366 related articles for article (PubMed ID: 28447479)
1. Autotaxin inhibitors: a patent review (2012-2016).
Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
[TBL] [Abstract][Full Text] [Related]
2. Autotaxin inhibitors: a patent review.
Barbayianni E; Magrioti V; Moutevelis-Minakakis P; Kokotos G
Expert Opin Ther Pat; 2013 Sep; 23(9):1123-32. PubMed ID: 23641951
[TBL] [Abstract][Full Text] [Related]
3. An updated patent review of autotaxin inhibitors (2017-present).
Tan Z; Lei H; Guo M; Chen Y; Zhai X
Expert Opin Ther Pat; 2021 May; 31(5):421-434. PubMed ID: 33342311
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis.
Ninou I; Kaffe E; Müller S; Budd DC; Stevenson CS; Ullmer C; Aidinis V
Pulm Pharmacol Ther; 2018 Oct; 52():32-40. PubMed ID: 30201409
[TBL] [Abstract][Full Text] [Related]
5. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
[TBL] [Abstract][Full Text] [Related]
6. Autotaxin in liver fibrosis.
Ikeda H; Yatomi Y
Clin Chim Acta; 2012 Nov; 413(23-24):1817-21. PubMed ID: 22820036
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent inhibitors of the lysophospholipase autotaxin.
Shah P; Cheasty A; Foxton C; Raynham T; Farooq M; Gutierrez IF; Lejeune A; Pritchard M; Turnbull A; Pang L; Owen P; Boyd S; Stowell A; Jordan A; Hamilton NM; Hitchin JR; Stockley M; MacDonald E; Quesada MJ; Trivier E; Skeete J; Ovaa H; Moolenaar WH; Ryder H
Bioorg Med Chem Lett; 2016 Nov; 26(22):5403-5410. PubMed ID: 27780639
[TBL] [Abstract][Full Text] [Related]
8. Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.
Nikolaou A; Ninou I; Kokotou MG; Kaffe E; Afantitis A; Aidinis V; Kokotos G
J Med Chem; 2018 Apr; 61(8):3697-3711. PubMed ID: 29620892
[TBL] [Abstract][Full Text] [Related]
9. Designing Dual Inhibitors of Autotaxin-LPAR GPCR Axis.
Banerjee S; Lee S; Norman DD; Tigyi GJ
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080255
[TBL] [Abstract][Full Text] [Related]
10. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis.
Gotoh M; Fujiwara Y; Yue J; Liu J; Lee S; Fells J; Uchiyama A; Murakami-Murofushi K; Kennel S; Wall J; Patil R; Gupte R; Balazs L; Miller DD; Tigyi GJ
Biochem Soc Trans; 2012 Feb; 40(1):31-6. PubMed ID: 22260662
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis.
Oikonomou N; Mouratis MA; Tzouvelekis A; Kaffe E; Valavanis C; Vilaras G; Karameris A; Prestwich GD; Bouros D; Aidinis V
Am J Respir Cell Mol Biol; 2012 Nov; 47(5):566-74. PubMed ID: 22744859
[TBL] [Abstract][Full Text] [Related]
12. Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer.
Barbayianni E; Kaffe E; Aidinis V; Kokotos G
Prog Lipid Res; 2015 Apr; 58():76-96. PubMed ID: 25704398
[TBL] [Abstract][Full Text] [Related]
13. Development and therapeutic potential of autotaxin small molecule inhibitors: From bench to advanced clinical trials.
Matralis AN; Afantitis A; Aidinis V
Med Res Rev; 2019 May; 39(3):976-1013. PubMed ID: 30462853
[TBL] [Abstract][Full Text] [Related]
14. Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors.
Joncour A; Desroy N; Housseman C; Bock X; Bienvenu N; Cherel L; Labeguere V; Peixoto C; Annoot D; Lepissier L; Heiermann J; Hengeveld WJ; Pilzak G; Monjardet A; Wakselman E; Roncoroni V; Le Tallec S; Galien R; David C; Vandervoort N; Christophe T; Conrath K; Jans M; Wohlkonig A; Soror S; Steyaert J; Touitou R; Fleury D; Vercheval L; Mollat P; Triballeau N; van der Aar E; Brys R; Heckmann B
J Med Chem; 2017 Sep; 60(17):7371-7392. PubMed ID: 28731719
[TBL] [Abstract][Full Text] [Related]
15. Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.
Stein AJ; Bain G; Prodanovich P; Santini AM; Darlington J; Stelzer NM; Sidhu RS; Schaub J; Goulet L; Lonergan D; Calderon I; Evans JF; Hutchinson JH
Mol Pharmacol; 2015 Dec; 88(6):982-92. PubMed ID: 26371182
[TBL] [Abstract][Full Text] [Related]
16. Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.
Ragle LE; Palanisamy DJ; Joe MJ; Stein RS; Norman DD; Tigyi G; Baker DL; Parrill AL
Bioorg Med Chem; 2016 Oct; 24(19):4660-4674. PubMed ID: 27544588
[TBL] [Abstract][Full Text] [Related]
17. Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis: limiting fibrosis by limiting lysophosphatidic acid synthesis.
Tager AM
Am J Respir Cell Mol Biol; 2012 Nov; 47(5):563-5. PubMed ID: 23125419
[No Abstract] [Full Text] [Related]
18. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
[TBL] [Abstract][Full Text] [Related]
19. [Function and biological activities of the autotaxin-LPA axis].
Li ZW; Zhao YR; Zhao C; Fu R; Li ZY
Sheng Li Xue Bao; 2011 Dec; 63(6):601-10. PubMed ID: 22193457
[TBL] [Abstract][Full Text] [Related]
20. Autotaxin and LPA receptor signaling in cancer.
Houben AJ; Moolenaar WH
Cancer Metastasis Rev; 2011 Dec; 30(3-4):557-65. PubMed ID: 22002750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
